Patented Myopia Treatment Is Obvious, Petitioner Tells Board
(February 19, 2021, 1:02 PM EST) -- ALEXANDRIA, Va. — In a Feb. 17 petition for inter partes review (IPR), a pharmaceutical company maintains that the Patent Trial and Appeal Board should cancel 19 claims of a patented...
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login